Antares Pharma, Inc. announced that the U.S. Food and Drug Administration has approved TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Lipocine licensed the exclusive U.S. commercialization rights for TLANDO™ to Antares Pharma.